Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.30 is 98% above its 5-year average of -105.56, near the high end of its 5-year range (-205.97–-2.30).
67.03% above its 12-month average of -6.97.
Reported quarterly EPS; no daily interpolation. Q1 FY2027 (2026-07-31): -0.68.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 35 comparable quarters.
EARNINGS PER SHARE (EPS)
-2.30
EARNINGS PER SHARE (EPS) AVG TTM
-6.97
EARNINGS PER SHARE (EPS) AVG 3Y
-88.06
EARNINGS PER SHARE (EPS) AVG 5Y
-105.56
EARNINGS PER SHARE (EPS) AVG 10Y
-84.52
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+67.03%
CURRENT VS 3Y AVG
+97.39%
CURRENT VS 5Y AVG
+97.82%
CURRENT VS 10Y AVG
+97.28%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Alzamend Neuro Inc
Market Cap
$5.36M
Earnings Per Share (EPS)
-2.30
TTM Avg
-6.97
3Y Avg
-88.06
5Y Avg
-105.56
Market Cap
$5.21M
Earnings Per Share (EPS)
-4.53
TTM Avg
-13.96
3Y Avg
-30.40
5Y Avg
-166.98
Market Cap
$5.63M
Earnings Per Share (EPS)
-3.55
TTM Avg
-11.46
3Y Avg
-17.07
5Y Avg
-17.09
Market Cap
$4.99M
Earnings Per Share (EPS)
N/A
TTM Avg
0.00
3Y Avg
-0.12
5Y Avg
-0.11
Market Cap
$4.96M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.61
3Y Avg
-0.43
5Y Avg
-0.43
Market Cap
$4.85M
Earnings Per Share (EPS)
-6.95
TTM Avg
-22.18
3Y Avg
-69.66
5Y Avg
-91.58
Market Cap
$4.79M
Earnings Per Share (EPS)
-3.64
TTM Avg
-254.03
3Y Avg
-3442.01
5Y Avg
-5629.67
Market Cap
$6.03M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.92
3Y Avg
-0.62
5Y Avg
-0.53
Market Cap
$6.09M
Earnings Per Share (EPS)
537.52
TTM Avg
197.33
3Y Avg
123.75
5Y Avg
69.48
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alzamend Neuro Inc (ALZN) | $5.36M | -2.30 | -6.97 | -88.06 | -105.56 |
| Imunon, Inc. (IMNN)vs › | $5.21M | -4.53 | -13.96 | -30.40 | -166.98 |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | -3.55 | -11.46 | -17.07 | -17.09 |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | N/A | 0.00 | -0.12 | -0.11 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | N/A | -1.61 | -0.43 | -0.43 |
| CalciMedica, Inc. (CALC)vs › | $4.85M | -6.95 | -22.18 | -69.66 | -91.58 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | -3.64 | -254.03 | -3442.01 | -5629.67 |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.03M | N/A | -0.92 | -0.62 | -0.53 |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | 537.52 | 197.33 | 123.75 | 69.48 |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | -2.92 | -6.51 | -19.53 | -13.36 |
Trailing EPS (TTM)
$-2.30
Forward EPS (Est.)
$-1.05
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2026-04-30 | -2.63 |
| 2025-04-30 | -11.32 |
| 2024-04-30 | -132.33 |
| 2023-04-30 | -205.97 |
| 2022-04-30 | -187.31 |
| 2021-04-30 | -93.78 |
| 2020-04-30 | -83.56 |
| 2019-04-30 | -111.56 |
| 2018-04-30 | -27.71 |
| 2017-04-30 | -73.59 |
| 2016-04-30 | 0.00 |
